References

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

10.1016/s1470-2045(19)30626-6 · 2019 · External reference

Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study

10.1200/jco.21.01926 · 2022 · External reference

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

10.1016/s1470-2045(20)30110-8 · 2020 · External reference

Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802)

10.1038/s43018-025-00918-1 · 2025 · External reference

Harnessing innate immune pathways for therapeutic advancement in cancer

10.1038/s41392-024-01765-9 · 2024 · External reference

The complementarity of DDR, nucleic acids and anti-tumour immunity

10.1038/s41586-023-06069-6 · 2023 · External reference

Inflammatory microenvironment remodelling by tumour cells after radiotherapy

10.1038/s41568-020-0246-1 · 2020 · External reference

DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer

10.1038/s41392-020-0150-x · 2020 · External reference

Radiotherapy combined with immunotherapy: the dawn of cancer treatment

10.1038/s41392-022-01102-y · 2022 · External reference

Type I interferon-mediated tumor immunity and its role in immunotherapy

10.1007/s00018-022-04219-z · 2022 · External reference

Immunotherapy resistance in esophageal cancer: possible mechanisms and clinical implications

10.3389/fimmu.2022.975986 · 2022 · External reference

Immune evasion in esophageal squamous cell cancer: from the perspective of tumor microenvironment

10.3389/fonc.2022.1096717 · 2023 · External reference

DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts

10.1016/j.cell.2015.07.056 · 2015 · External reference

Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer

10.1158/2159-8290.cd-18-1020 · 2019 · External reference

Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade

10.1038/s41586-018-0768-9 · 2019 · External reference

RNA sensing induced by chromosome missegregation augments anti-tumor immunity

10.1016/j.molcel.2024.11.025 · 2025 · External reference

SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion

10.1016/j.cell.2024.01.008 · 2024 · External reference

Disulfiram/copper triggers cGAS-STING innate immunity pathway via ROS-induced DNA damage that potentiates antitumor response to PD-1 checkpoint blockade

10.7150/ijbs.105575 · 2025 · External reference

VDAC2 loss elicits tumour destruction and inflammation for cancer therapy

10.1038/s41586-025-08732-6 · 2025 · External reference

DNA/RNA-binding protein KIN17 supports esophageal cancer progression via resolving noncanonical STING activation induced by R-loop

10.1038/s41392-025-02344-2 · 2025 · External reference

High mobility group A1 (HMGA1) promotes esophageal squamous cell carcinoma progression by inhibiting STING-mediated anti-tumor immunity

10.1038/s41467-025-60221-6 · 2025 · External reference

ΔNp63-restricted viral mimicry response impedes cancer cell viability and remodels tumor microenvironment in esophageal squamous cell carcinoma

10.1016/j.canlet.2024.216999 · 2024 · External reference

Overactivation of XBP1 in plasma cells implies worse survival through innate immunity in esophageal squamous cell carcinoma

10.1016/j.canlet.2024.217045 · 2024 · External reference

Asparagine drives immune evasion in bladder cancer via RIG-I stability and type I IFN signaling

10.1172/jci186648 · 2025 · External reference

Targeting DHX9 triggers tumor-intrinsic interferon response and replication stress in small cell lung cancer

10.1158/2159-8290.cd-23-0486 · 2024 · External reference

Targeting TREX1 induces innate immune response in drug-resistant small-cell lung cancer

10.1158/2767-9764.crc-24-0360 · 2024 · External reference

NOTCH1 mutation and survival analysis of tislelizumab in advanced or metastatic esophageal squamous cell carcinoma: a biomarker analysis from the randomized, phase III, RATIONALE-302 trial

10.1200/jco-24-01818 · 2025 · External reference

Long non-coding RNA GAS5 is induced by interferons and plays an antitumor role in esophageal squamous cell carcinoma

10.1002/cam4.1524 · 2018 · External reference

Depletion of DNA polymerase theta inhibits tumor growth and promotes genome instability through the cGAS-STING-ISG pathway in esophageal squamous cell carcinoma

10.3390/cancers13133204 · 2021 · External reference

Senescent SPP1+ macrophages remodel the tumor microenvironment and promote the progression of early-stage lung adenocarcinoma featured with mixed ground glass nodule

10.1186/s12943-025-02497-2 · 2025 · External reference

A comparison of the absorption and metabolism of the major quercetin in brassica, quercetin-3-O-sophoroside, to that of quercetin aglycone, in rats

10.1016/j.foodchem.2019.125880 · 2020 · External reference

Oncogenic KRAS drives immunosuppression of colorectal cancer by impairing DDX60-mediated dsRNA accumulation and viral mimicry

10.1126/sciimmunol.ado8758 · 2024 · External reference

MCM6 is a critical transcriptional target of YAP to promote gastric tumorigenesis and serves as a therapeutic target

10.7150/thno.75431 · 2022 · External reference

The HP1alpha-CAF1-SetDB1-containing complex provides H3K9me1 for Suv39-mediated K9me3 in pericentric heterochromatin

10.1038/embor.2009.90 · 2009 · External reference

The histone chaperone CAF-1 safeguards somatic cell identity

10.1038/nature15749 · 2015 · External reference

MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response

10.1016/j.cell.2011.06.041 · 2011 · External reference

Upstream ORFs prevent MAVS spontaneous aggregation and regulate innate immune homeostasis

10.1016/j.isci.2020.101059 · 2020 · External reference

A bicistronic MAVS transcript highlights a class of truncated variants in antiviral immunity

10.1016/j.cell.2014.01.021 · 2014 · External reference

Positive feedback regulation of type I IFN production by the IFN-inducible DNA sensor cGAS

10.4049/jimmunol.1402066 · 2015 · External reference

Nucleosome disassembly during human non-homologous end joining followed by concerted HIRA- and CAF-1-dependent reassembly

10.7554/elife.15129 · 2016 · External reference

Chromatin assembly factors Asf1 and CAF-1 have overlapping roles in deactivating the DNA damage checkpoint when DNA repair is complete

10.1073/pnas.0812578106 · 2009 · External reference

Regulation of oxidized base damage repair by chromatin assembly factor 1 subunit A

10.1093/nar/gkw1024 · 2017 · External reference

The histone chaperones ASF1 and CAF-1 promote MMS22l-TONSL-mediated Rad51 loading onto ssDNA during homologous recombination in human cells

10.1016/j.molcel.2018.01.031 · 2018 · External reference

CHAF1A interacts with TCF4 to promote gastric carcinogenesis via upregulation of c-MYC and CCND1 expression

10.1016/j.ebiom.2018.11.009 · 2018 · External reference

Inhibition of CAF-1 histone chaperone complex triggers cytosolic DNA and dsRNA sensing pathways and induces intrinsic immunity of hepatocellular carcinoma

10.1097/hep.0000000000000709 · 2024 · External reference

CHAF1A blocks neuronal differentiation and promotes neuroblastoma oncogenesis via metabolic reprogramming

10.1002/advs.202005047 · 2021 · External reference